1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of ABBV-383, a BCMA bispecific antibody, in black patients with relapsed/refractory multiple myeloma: A subgroup analysis of a phase 1 trial
    Meeting Abstract

    D'Souza, A.; Rodriguez-Valdes, C.; Kumar, S.; Chung, A.; Tuchman, S.; Safah, H.; Weisel, K.; Teipel, R.; Korde, N.; Vij, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Rajeeve, S.; Jurgens, E.; Nishimura, N.; Farzana, T.; Firestone, R.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Tan, C.; Shekarkhand, T.; Firestone, R.; Jurgens, E.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; Rajeeve, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed/refractory multiple myeloma harboring t(11;14)
    Meeting Abstract

    Costa, A.; Dhakal, B.; Hultcrantz, M.; Bal, S.; Chuah, H.; Kaufman, J. L.; Kazandjian, D.; Nathwani, N.; Royle, G.; Sborov, D. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Interim results of a phase 2 trial of isatuximab-lenalidomide for patients with High-Risk Smoldering Multiple Myeloma
    Meeting Abstract

    Thomas, S.; Manasanch, E.; Korde, N.; Lee, H.; Jagannath, S.; Becnel, M.; Kaufman, G.; Patel, K.; Iyer, S.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Para-medullary (PMD) and extra-medullary (EMD) myeloma demonstrate increased copy number aberration, mutational burden, structural variants and genomic complexity compared to marrow-based myeloma
    Meeting Abstract

    Maclachlan, K.; Garcés, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Maintenance therapy cessation for multiple myeloma patients with three-year sustained mrd negative remissions
    Meeting Abstract

    Korde, N.; Hassoun, H.; Landau, H.; Hamid, S.; Derkach, A.; Hultcrantz, M.; Mailankody, S.; Tan, C.; Shah, U.; Maclachlan, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world incidence and prevention of tumor lysis syndrome in chronic lymphocytic leukemia treated with venetoclax
    Journal Article

    Valtis, Y. K.; Nemirovsky, D.; Derkach, A.; Sharan, S.; Kabel, C.; Ortiz, R.; Thompson, M. C.; Roeker, L. E.; Geyer, M. B.
    Blood Advances (2024)

    Fulltext@MSK | Save
  • ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome
    Guidelines

    Goyal, A.; O'Leary, D.; Dabaja, B.; Weng, W. K.; Zain, J.; Cutler, C.; Guitart, J.; Kim, Y. H.; Geskin, L. J.; Hoppe, R. T.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab
    Journal Article

    Lochrin, S. E.; Buonocore, D. J.; Young, R. J.; Kaley, T. J.; Postow, M. A.; Wolchok, J. D.; Shoushtari, A. N.; Momtaz, P.; Betof Warner, A. S.; Callahan, M. K.
    Pigment Cell & Melanoma Research (2024)

    Fulltext@MSK | Save